会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • AZABICYCLO (3.1.0) HEXANE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS
    • AZ Y Y O O O O S S S S S S S S S S S S S S S S S S S S S S S S S S
    • WO2005080382A1
    • 2005-09-01
    • PCT/EP2005/001940
    • 2005-02-21
    • GLAXO GROUP LIMITEDARISTA, LucaBONANOMI, GiorgioCAPELLI, Anna MariaDAMIANI, FedericaDI FABIO, RomanoGENTILE, GabriellaHAMPRECHT, DieterMICHELI, FabrizioTARSI, LucaTEDESCO, GiovannaTERRENI, Silvia
    • ARISTA, LucaBONANOMI, GiorgioCAPELLI, Anna MariaDAMIANI, FedericaDI FABIO, RomanoGENTILE, GabriellaHAMPRECHT, DieterMICHELI, FabrizioTARSI, LucaTEDESCO, GiovannaTERRENI, Silvia
    • C07D403/12
    • C07D495/04C07D401/14C07D403/04C07D403/12C07D403/14C07D405/14C07D413/14C07D417/14C07D471/08
    • The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein G is selected from a group consisting of: phenyl, pyridyl, benzothiazolyl, indazolyl; p is an integer ranging from 0 to 5; R 1 is independently selected from a group consisting of: halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl; or corresponds to a group R 5 ; R 2 is hydrogen or C 1-4 alkyl; R 3 is C 1-4 alkyl; R 4 is hydrogen, or a phenyl group, a heterocyclyl group, a 5- or 6-membered heteroaromatic group, or a 8- to 11-membered bicyclic group, any of which groups is optionally substituted by 1, 2, 3 or 4 substituents selected from the group consisting of: halogen, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl; R 5 is a moiety selected from the group consisting of: isoxazolyl, -CH 2 -N-pyrrolyl, 1,1-dioxido-2-isothiazolidinyl, thienyl, thiazolyl, pyridyl, 2-pyrrolidinonyl, and such a group is optionally substituted by one or two substituents selected from: halogen, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, C 1-4 alkanoyl; and when R 1 is chlorine and p is 1, such R 1 is not present in the ortho position with respect to the linking bond to the rest of the molecule; and when R 1 corresponds to R 5 , p is 1; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as modulators of dopamine D 3 receptors, e.g. to treat drug dependency or as antipsychotic agents.
    • 本发明涉及新的式(I)化合物或其药学上可接受的盐,其中G选自:苯基,吡啶基,苯并噻唑基,吲唑基; p为0〜5的整数; R 1独立地选自:卤素,羟基,氰基,C 1-4烷基,卤代C 1-4烷基,C 1-4烷氧基,卤代C 1-4烷氧基,C 1-4烷酰基; 或对应于R5组; R2是氢或C1-4烷基; R3是C1-4烷基; R 4是氢或苯基,杂环基,5或6元杂芳族基团或8至11元双环基团,其中任何基团任选被1,2,3或4个取代基取代 选自:卤素,氰基,C 1-4烷基,卤代C 1-4烷基,C 1-4烷氧基,C 1-4烷酰基; R5是选自以下的部分:异恶唑基,-CH 2 -N-吡咯基,1,1-二氧化-2-异噻唑烷基,噻吩基,噻唑基,吡啶基,2-吡咯烷酮基,任选地被一个或多个 选自以下的两个取代基:卤素,氰基,C 1-4烷基,卤代C 1-4烷基,C 1-4烷氧基,C 1-4烷酰基; 当R1为氯且p为1时,该R1不存在于与分子的其余部分的连接键的邻位; 当R1对应于R5时,p为1; 它们的制备方法,这些方法中使用的中间体,含有它们的药物组合物及其在治疗中的用途,作为多巴胺D3受体的调节剂。 治疗药物依赖或作为抗精神病药。
    • 5. 发明申请
    • COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF
    • 在5HT2C受体上具有活性的化合物及其用途
    • WO2004078718A1
    • 2004-09-16
    • PCT/EP2004/001843
    • 2004-02-24
    • GLAXO GROUP LIMITEDDAMIANI, FedericaHAMPRECHT, DieterMICHELI, FabrizioPASQUARELLO, AlessandraTEDESCO, Giovanna
    • DAMIANI, FedericaHAMPRECHT, DieterMICHELI, FabrizioPASQUARELLO, AlessandraTEDESCO, Giovanna
    • C07D207/26
    • C07D207/26C07D207/273C07D207/38
    • Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed, wherein R 1 is hydrogen, fluoro, chloro, hydroxy, C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, C 1-6 alkoxy or haloC 1-6 alkoxy; m is 0 when ==== is a double bond and m is 1 when ==== is a single bond; R 2 is hydrogen, halogen, cyano, nitro, C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, C 1-6 alkylthio, amino, mono- or di-C 1-6 alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is -(CH 2 -CH 2 )-, -(CH=CH)-, -(CH 2 ) 3 -, -C(CH 3 ) 2 -, -(CH=CH-CH 2 )-, -(CH 2 -CH=CH)- or a group -(CHR 5 )- wherein R 5 is hydrogen, halogen, hydroxy, cyano, nitro, C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy or C 1-6 alkylthio; R 3 is halogen, cyano, C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, C 1-6 alkoxy, C 1-6 alkylthio, hydroxy, amino, mono- or di-C 1-6 alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC 1-6 alkyl, haloC 1-6 alkoxy, aryl, arylC 1-6 alkyl, arylC 1-6 alkyloxy, arylC 1-6 alkylthio or COOR 6 , CONR 7 R 8 or COR 9 wherein R 6 , R 7 , R 8 and R 9 are independently hydrogen or C 1-6 alkyl; p is 0, 1 or 2 or 3; R 4 is hydrogen, halogen, hydroxy, cyano, nitro, C 1-6 alkyl, C 1-6 alkanoyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, C 1-6 alkylthio, amino, mono- or di-C 1-6 alkylamino or an N-linked 4 to 7 membered heterocyclic group; Y is oxygen, sulfur, -CH 2 - or NR 10 wherein R 10 is hydrogen or C 1-6 alkyl; D is a single bond, -CH 2 -, -(CH 2 ) 2 - or -CH=CH-; and Z is -NR 11 R 12 where R 11 and R 12 are independently hydrogen or C 1-6 alkyl, or an optionally substituted N-linked or C-linked 4 to 7 membered heterocyclic group. Method of preparation and uses of the compounds in therapy, for example depression and anxiety, are also disclosed.
    • 公开了式(I)化合物及其药学上可接受的盐,其中R 1是氢,氟,氯,羟基,C 1-6烷基,C 3-7环烷基,C 3-7环烷氧基,C 1-6烷氧基或卤代C 1-6烷氧基; 当====为双键时,m为0,当==为单键时,m为1; R2是氢,卤素,氰基,硝基,C1-6烷基,C3-7环烷基,C3-7环烷氧基,卤代C 1-6烷基,C 1-6烷氧基,卤代C 1-6烷氧基,C 1-6烷硫基,氨基,单或二C 1-6烷基氨基或 N-连接的4至7元杂环基; X是 - (CH 2 -CH 2) - , - (CH = CH) - , - (CH 2)3 - , - C(CH 3)2 - , - (CH = CH-CH 2) - , - (CH 2 -CH = CH ) - 或基 - (CHR 5) - ,其中R 5是氢,卤素,羟基,氰基,硝基,C 1-6烷基,C 3-7环烷基,C 3-7环烷氧基,卤代C 1-6烷基,C 1-6烷氧基,卤代C 1-6烷氧基或C 1-6烷硫基 ; R 3是卤素,氰基,C 1-6烷基,C 3-7环烷基,C 3-7环烷氧基,C 1-6烷氧基,C 1-6烷硫基,羟基,氨基,单 - 或二-C 1-6烷基氨基,N-连接的4-7元杂环基, 硝基,卤代C 1-6烷基,卤代C 1-6烷氧基,芳基,芳基C 1-6烷基,芳基C 1-6烷氧基,芳基C 1-6烷硫基或COOR 6,CONR 7 R 8或COR 9,其中R 6,R 7,R 8和R 9独立地为氢或C 1-6烷基; p为0,1或2或3; R4是氢,卤素,羟基,氰基,硝基,C1-6烷基,C1-6烷酰基,C3-7环烷基,C3-7环烷氧基,卤代C 1-6烷基,C 1-6烷氧基,卤代C 1-6烷氧基,C 1-6烷硫基,氨基,单或二 C 1-6烷基氨基或N-连接的4至7元杂环基; Y是氧,硫,-CH 2 - 或NR 10,其中R 10是氢或C 1-6烷基; D是单键,-CH 2 - , - (CH 2)2 - 或-CH = CH-; 并且Z为-NR 11 R 12,其中R 11和R 12独立地为氢或C 1-6烷基,或任选取代的N-连接或C连接的4至7元杂环基。 还公开了化合物在治疗中的制备和用途的方法,例如抑郁和焦虑。
    • 6. 发明申请
    • COMPOUNDS HAVING AFFINITY AT 5HT2C RECEPTOR AND USE THEREOF IN THERAPY
    • 在5HT2C受体中具有亲和力的化合物及其治疗用途
    • WO2003089409A1
    • 2003-10-30
    • PCT/EP2003/004180
    • 2003-04-17
    • GLAXO GROUP LIMITEDDAMIANI, FedericaHAMPRECHT, DieterJAXA-CHAMIEC, Albert, AndrzejMICHELI, FabrizioPASQUARELLO, AlessandraTEDESCO, Giovanna
    • DAMIANI, FedericaHAMPRECHT, DieterJAXA-CHAMIEC, Albert, AndrzejMICHELI, FabrizioPASQUARELLO, AlessandraTEDESCO, Giovanna
    • C07D207/26
    • C07D207/26C07D207/273C07D207/38C07D211/76C07D211/88C07D401/12
    • Compounds of formula (I) or a pharmaceutically acceptable salt thereof are disclosed: wherein R 1 is hydrogen, hydroxy, fluoro, chloro, C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, C 1-6 alkoxy or haloC 1-6 alkoxy; m is 0 when ======= is a double bond and m is 1 when ======= is a single bond; R 2 is hydrogen, halogen, cyano, nitro, C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, C 1-6 alkylthio, amino, mono- or di-C 1-6 alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is -(CH 2 -CH 2 )-, -(CH=CH)-, -(CH 2 ) 3 -, -C(CH 3 ) 2 -, -(CH=CH-CH 2 )-, -(CH 2 -CH=CH)- or a group -(CHR 5 )- wherein R 5 is hydrogen, halogen, hydroxy, cyano, nitro, C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy or C 1-6 alkylthio; R 3 is halogen, cyano, C 1-6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, C 1-6 alkoxy, C 1-6 alkylthio, hydroxy, amino, mono- or di-C 1-6 alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC 1-6 alkyl, haloC 1-6 alkoxy, aryl, arylC 1-6 alkyl, arylC 1-6 alkyloxy, arylC 1-6 alkylthio or COOR 6 , CONR 7 R 8 or COR 9 wherein R 6 , R 7 , R 8 and R 9 are independently hydrogen or C 1-6 alkyl; p is 0, 1 or 2 or 3; R 4 is hydrogen, halogen, hydroxy, cyano, nitro, C 1-6 alkyl, C 1-6 alkanoyl, C 3-7 cycloalkyl, C 3-7 cycloalkyloxy, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, C 1-6 alkylthio, amino, mono- or di-C 1-6 alkylamino or an N-linked 4 to 7 membered heterocyclic group; Y is oxygen, sulfur, -CH 2 - or NR 10 wherein R 10 is hydrogen or C 1-6 alkyl; D is a single bond, -CH 2 -, -(CH 2 ) 2 - or -CH=CH-; and Z is an optionally substituted C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, an optionally substituted N-linked 4 to 7 membered heterocyclic group, or Z is -NR 11 R 12 where R 11 and R 12 are independently hydrogen or C 1-6 alkyl. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression and anxiety, are also disclosed.
    • 公开了式(I)化合物或其药学上可接受的盐:其中R 1是氢,羟基,氟,氯,C 1-6烷基,C 3-7环烷基,C 3-7环烷氧基,C 1-6烷氧基或卤代C 1-6烷氧基; 当<=======>是双键时,m为0,当<=======>为单键时,m为1; R2是氢,卤素,氰基,硝基,C1-6烷基,C3-7环烷基,C3-7环烷氧基,卤代C 1-6烷基,C 1-6烷氧基,卤代C 1-6烷氧基,C 1-6烷硫基,氨基,单或二C 1-6烷基氨基或 N-连接的4至7元杂环基; X是 - (CH 2 -CH 2) - , - (CH = CH) - , - (CH 2)3 - , - C(CH 3)2 - , - (CH = CH-CH 2) - , - (CH 2 -CH = CH ) - 或基 - (CHR 5) - ,其中R 5是氢,卤素,羟基,氰基,硝基,C 1-6烷基,C 3-7环烷基,C 3-7环烷氧基,卤代C 1-6烷基,C 1-6烷氧基,卤代C 1-6烷氧基或C 1-6烷硫基 ; R 3是卤素,氰基,C 1-6烷基,C 3-7环烷基,C 3-7环烷氧基,C 1-6烷氧基,C 1-6烷硫基,羟基,氨基,单 - 或二-C 1-6烷基氨基,N-连接的4-7元杂环基, 硝基,卤代C 1-6烷基,卤代C 1-6烷氧基,芳基,芳基C 1-6烷基,芳基C 1-6烷氧基,芳基C 1-6烷硫基或COOR 6,CONR 7 R 8或COR 9,其中R 6,R 7,R 8和R 9独立地为氢或C 1-6烷基; p为0,1或2或3; R4是氢,卤素,羟基,氰基,硝基,C1-6烷基,C1-6烷酰基,C3-7环烷基,C3-7环烷氧基,卤代C 1-6烷基,C 1-6烷氧基,卤代C 1-6烷氧基,C 1-6烷硫基,氨基,单或二 C 1-6烷基氨基或N-连接的4至7元杂环基; Y是氧,硫,-CH 2 - 或NR 10,其中R 10是氢或C 1-6烷基; D是单键,-CH 2 - , - (CH 2)2 - 或-CH = CH-; Z为含有至少一个氮原子,任意取代的N-连接的4-7元杂环基的任意取代的C连接的4至7元杂环基,或Z为-NR 11 R 12,其中R 11和R 12独立地为氢或C 1-6烷基 。 还公开了其治疗方法及其在治疗中的用途,特别是CNS疾病如抑郁和焦虑。
    • 10. 发明公开
    • COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF
    • AN 5HT 2C受体活性化合物和用途
    • EP1599445A1
    • 2005-11-30
    • EP04713874.8
    • 2004-02-24
    • GLAXO GROUP LIMITED
    • DAMIANI, FedericaHAMPRECHT, DieterMICHELI, FabrizioPASQUARELLO, AlessandraTEDESCO, Giovanna
    • C07D207/26C07D207/38A61K31/40
    • C07D207/26C07D207/273C07D207/38
    • Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed, wherein R1 is hydrogen, fluoro, chloro, hydroxy, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, C1-6alkoxy or haloC1-6alkoxy; m is 0 when ==== is a double bond and m is 1 when ==== is a single bond; R2 is hydrogen, halogen, cyano, nitro, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1-6alkylthio, amino, mono- or di-C1-6alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is -(CH2-CH2)-, -(CH=CH)-, -(CH2)3-, -C(CH3)2-, -(CH=CH-CH2)-, -(CH2-CH=CH)- or a group -(CHR5)- wherein R5 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy or C1-6alkylthio; R3 is halogen, cyano, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, C1-6alkoxy, C1-6alkylthio, hydroxy, amino, mono- or di-C1-6alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC1-6alkyl, haloC1-6alkoxy, aryl, arylC1-6alkyl, arylC1-6alkyloxy, arylC1-6alkylthio or COOR6, CONR7R8 or COR9 wherein R6, R7, R8 and R9 are independently hydrogen or C1-6alkyl; p is 0, 1 or 2 or 3; R4 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C1-6alkanoyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1-6alkylthio, amino, mono- or di-C1-6alkylamino or an N-linked 4 to 7 membered heterocyclic group; Y is oxygen, sulfur, -CH2- or NR10 wherein R10 is hydrogen or C1-6alkyl; D is a single bond, -CH2-, -(CH2)2- or -CH=CH-; and Z is -NR11R12 where R11 and R12 are independently hydrogen or C1-6alkyl, or an optionally substituted N-linked or C-linked 4 to 7 membered heterocyclic group. Method of preparation and uses of the compounds in therapy, for example depression and anxiety, are also disclosed.